Is Nuvation Bio Inc. (NUVB) a Buy, Sell, or Hold?
Nuvation Bio Inc.
NYSE:NUVB
$5.9 USD
$0.13 (2.25%)
- Volume
- 7.29M
- Average Volume
- 5.89M
- Market Capitalization
- $2.05B
- P/E Ratio
- -13.90
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $9.75
- Year Low
- $2.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.44
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | David T. Hung |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NUVB |
| CUSIP | 67080N101 |
| CIK | 0001811063 |
| Web | https://www.nuvationbio.com |
| Phone | 332 208 6102 |
| Currency | USD |
| Employees | 307 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.44 |
| Quick Ratio | 7.24 |
| Cash Ratio | 1.58 |
Sales & Book Value
| Annual Sales | $62.9M |
| Price / Sales | 14.32 |
| Cash Flow | -0.36 |
| Price / Cash Flow | -16.25 |
| Price / Book | 6.41 |
Price Target and Rating
| Average Stock Price Forecast | $16.00 |
| High Stock Price Forecast | $19.00 |
| Low Stock Price Forecast | $13.00 |
| Forecast Upside/Downside | -63.13% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.6 |
| Trailing P/E Ratio | -13.90 |
| PEG Ratio | -0.10 |
| P/E Growth | -0.10 |
| Net Income | $-204.63M |
| Net Margin | -102.06% |
| Pretax Margin | -102.06% |
| Return on Equity | -44.10% |
| Return on Assets | -23.92% |
Financials Score
| AltmanZ Score | 2.15 |
| Piotroski Score | 3.00 |
| Working Capital | 512.01M |
| Total Assets | 610.24M |
| Ebit | -131.69M |
| Market Cap | 2.02B |
| Total Liabilities | 290.68M |
Poll Results
About Nuvation Bio Inc. (NYSE:NUVB) Stock
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a pol ... y ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
2026-07-06 17:09:00
NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032 (the "Notes"). The aggregate principal amount of Notes sold in the offering was $287.5 million, inclusive of the $37.5 million aggregate principal amount of Notes issued pursuant to the Greenshoe Exercise.
2026-06-29 19:19:05
According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a total value of $753,000 on June 23, 2026. This transaction represented 79.32% of Markel Stacy's direct Class A holdings, reducing the direct position to 32,591 shares, though she also retains significant exposure through stock options.
2026-06-29 08:00:00
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
2026-06-26 00:00:00
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR Newswire NEW
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
2026-06-25 23:58:00
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million.
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
2026-06-25 07:00:00
NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any.
Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum
2026-06-17 12:01:53
Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains.
Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level
2026-06-15 10:38:58
I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-driving oncology assets. NUVB's fundamentals hinge on Ibtrozi (taletrectinib), a next-gen ROS1 inhibitor now commercial, and safusidenib, a late-stage mutant IDH1 inhibitor. My sum-of-the-parts analysis yields a $5.6/share fair value, with further upside from M&A potential, re-rating anchored on recent M&A activity, and milestone payments.
Frequently Asked Questions
-
What is the current Nuvation Bio Inc. (NUVB) stock price?
-
Nuvation Bio Inc.(NYSE:NUVB) stock price is $5.9 in the last trading session. During the trading session, NUVB stock reached the peak price of $9.75 while $2.08 was the lowest point it dropped to. The percentage change in NUVB stock occurred in the recent session was 2.25% while the dollar amount for the price change in NUVB stock was $0.13.
-
NUVB's industry and sector of operation?
-
The NYSE listed NUVB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NUVB?
-
Gary Hattersley | Chief Scientific Officer
Kerry A. Wentworth | Chief Regulatory Officer
Robert DeVita | Vice President of Corporate Development & Investor Relations
David T. Hung | Founder, President, Chief Executive Officer & Chairman
Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer -
How many employees does NUVB have?
-
Number of NUVB employees currently stands at 307. NUVB operates from 1500 Broadway, New York City, NY 10036, US.
-
Link for NUVB official website?
-
Official Website of NUVB is: https://www.nuvationbio.com
-
How do I contact NUVB?
-
NUVB could be contacted at phone #332 208 6102 and can also be accessed through its website. NUVB operates from 1500 Broadway, New York City, NY 10036, US.
-
How many shares of NUVB are traded daily?
-
The average number of NUVB shares traded daily for last 3 months was 5.89M.
-
What is the market cap of NUVB currently?
-
The market value of NUVB currently stands at $2.05B with its latest stock price at $5.9